Aging and Longevity Support

Protocol development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.

To establish these protocols, we first developed a Rating Scale that could be used to discern the rigor of evidence supporting a specific nutrient’s therapeutic effect.

The following protocols were developed using only A through D-quality evidence.

Screen Shot 2020-06-03 at 11.30.07 AM.pn

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Multivitamin

Multivitamin formulation, minimum 8 weeks1

Multivitamin use was associated with longer telomere length in women aged 35 to 742
Multivitamins containing a combination of minerals and herbs were shown to decrease perceived mental stress in an elderly population several hours after intake4
Multivitamin intake in elderly women was associated with an increase in inhibitory neural processes, which translates into an improvement in neural efficiency during memory retrieval3
Multivitamins were shown to improve alertness and negative mood symptoms in men aged 50 to 69 years old1

Multivitamin in the Fullscript catalog.

Omega-3 fatty acids

1.25-2.5g of Omega-3 PUFA, total per day, minimum 8 weeks5,6,7

Omega-3 PUFA has been shown to increase telomerase levels and lengths5,6
Omega-3 PUFAs have shown to reduce IL-1β, TNF-α, and IL-6, factors that contribute to the effects of inflammaging7

For a more detailed review of Omega 3 fatty acids, refer to the Fullscript reference sheet: https://fullscript.com/hcp/fish-oil

Omega 3 fatty acids in the Fullscript catalog.

New and upcoming research:

Astragalus membracanus

10-50mg of TA-65, total per day, minimum 12 months8

Decline in the percentage of senescent cytotoxic T cells (CD8+ and CD28-) and natural killer cells were observed in seropositive patients9
TA-65 has been demonstrated a clinically significant effect in lengthening telomerase and decreasing the percentage of short telomerase8,9

Astragalus membracanus in the Fullscript catalog.

References

https://www.ncbi.nlm.nih.gov/pubmed/22095836

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714373/

https://www.ncbi.nlm.nih.gov/pubmed/22939764

https://www.ncbi.nlm.nih.gov/pubmed/25903286

https://www.ncbi.nlm.nih.gov/pubmed/29241838

https://www.ncbi.nlm.nih.gov/pubmed/23010452

https://www.ncbi.nlm.nih.gov/pubmed/29735019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178008/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045570/